Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
BörsenkürzelEVO
Name des UnternehmensEvotec SE
IPO-datumOct 11, 1999
CEOWojczewski (Christian)
Anzahl der mitarbeiter4827
WertpapierartDepository Receipt
GeschäftsjahresendeOct 11
AddresseEssener Bogen 7
StadtHAMBURG
BörseNASDAQ OMX - NASDAQ BASIC
LandGermany
Postleitzahl22419
Telefon4940560810
Websitehttps://www.evotec.com/
BörsenkürzelEVO
IPO-datumOct 11, 1999
CEOWojczewski (Christian)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten